Interest in coronary microembolization and its sequelae has fluctuated over time. In the 1980s, several investigators (notably Davies and Falk), performed autopsy studies in patients with coronary artery disease who had died suddenly. Together with the rupture or fissure of epicardial coronary atherosclerotic plaques1–3, obstruction of the coronary microcirculation by microemboli was frequently identified. These microemboli predominantly consisted of platelet aggregates, fibrin, hyalin and atherosclerotic plaque material, including cholesterol1–6. In the same decade, the development of platelet aggregation in the stenotic coronary arteries of dogs was characterized by Folts and Willerson. They identified endothelial dysfunction involving serotonin, thrombin and thromboxane A2 as mediators and causing cyclic flow variations with embolization of platelet aggregates into the microcirculation7–10.

With the increasing use of elective and primary percutaneous coronary intervention (PCI), interest in coronary microembolization was renewed in the early 2000s prompted by the question of what happened to plaque material that was released during PCI11,12. The use of protection devices during PCI enabled particulate plaque debris, thrombotic material and soluble factors to be retrieved from native and graft coronary vessels13. However, the clinical benefit of protection devices was modest at best, and interest in coronary microembolization understandably subsided.

During the past decade, several investigators (notably Libby) have emphasized an increasing incidence of plaque erosion rather than rupture as the key underlying event of acute coronary syndromes, particularly as a consequence of increasing statin use14–17. The increasing incidence of plaque erosion has been associated with a quantitative shift from ST-segment elevation myocardial infarction (STEMI) to non-ST-segment elevation myocardial infarction (NSTEMI) over the past 25 years15,16,18. Coronary microemboli are more frequently found at autopsy in patients with plaque erosion who have died suddenly than in those with plaque rupture19. The fact that not all patients with NSTEMI need routine intervention but do require intensified antithrombotic treatment20,21 places the spotlight on the obstruction and dysfunction of the coronary microcirculation. Indeed, the treatment of coronary microembolization is likely to be more important in the outcome of patients with acute coronary syndromes than during elective PCI. In this Review, we characterize the features and mechanisms of coronary microembolization and discuss clinical trials of drugs and devices for prevention and treatment.
Experimental coronary microembolization

Animal models. Intracoronary injection of inert particles (such as talcum, lycopodium spores or plastic microspheres of various diameters) in anaesthetized dogs has been used since the early twentieth century to study the effects of a fairly standardized, partial coronary obstruction on cardiac rhythm and contractile function, including cardiogenic shock22–29. Intracoronary injection of inert polystyrene microspheres is the current standard method of inducing a regional acute coronary syndrome30,31 and, with repetitive microembolization, heart failure32,33 in animal models (for example, dogs34–36, pigs37–40, sheep41, mice42 and rats43). The advantage of using polystyrene microspheres is that the diameter (usually around 40 μm) and the number of injected spheres can be standardized and adjusted to coronary inflow. The disadvantage of this method is the inert nature of these microspheres36, which cause physical obstruction of the coronary microcirculation but have no prothrombotic, pro-inflammatory or vasoconstrictor potential.

An alternative but somewhat less standardized approach is the intracoronary infusion of exogenously (ex vivo) generated homologous or autologous thrombotic material that, although not inert, still does not include atherosclerotic debris and soluble factors released from an atherosclerotic culprit lesion. This method has been used in rats44 and pigs45.

A model of severe epicardial coronary stenosis with endothelial dysfunction, developed by Folts et al.1, causes the spontaneous formation of platelet aggregates in the stenotic segment with progressive inflow reduction, followed by sudden restoration of blood flow when the platelet aggregate is dislodged from the stenotic segment and embolized into the coronary microcirculation. This model has been used in dogs46–48 and pigs46 and is characterized by cyclic coronary flow variations, which enable prothrombotic and vasoconstrictor factors, such as thrombin1, serotonin and thromboxane A2 (REF1), to be studied.

Blood flow and cardiac function. In anaesthetized dogs, intracoronary injection of inert microparticles results in an immediate decrease in coronary blood flow44,48, followed by reactive hyperaemia44,46,48 and then a return to normal blood flow44,46 (FIG. 1). Regional myocardial contractile function, as measured by sonomicrometry, in the perfusion territory of the embolized coronary artery decreases immediately, then partially recovers over minutes but does not return to baseline function46. The response of global left ventricular (LV) function depends on the number and size of embolizing particles and the size of the affected coronary perfusion territory. The response can range from transient and subtle LV dysfunction46 to protracted and severe cardiogenic shock46. With repetitive coronary microembolization, baseline coronary blood flow can still be normal or even above normal but coronary reserve in response to adenosine is markedly reduced46. Both the slightly increased baseline flow (reflecting reactive hyperaemia) and, more importantly, the reduced maximal blood flow secondary to physical obstruction of the coronary microvasculature contribute to reduced coronary reserve46. The reduction in regional contractile function with repetitive coronary microembolization is cumulative (FIG. 1), and repetitive coronary microembolization has become a standard method to induce LV dysfunction and heart failure42,43. The dissociation between profound contractile dysfunction and normal or even slightly elevated coronary blood flow (that is, a perfusion–contraction mismatch pattern), is a salient feature of microembolized myocardium42,43.

Morphological sequelae. Coronary arterioles are functional end arteries, and their physical obstruction causes microinfarction (FIG. 2). The size of the microinfarcted area corresponds to the site of vascular obstruction which, in turn, is determined by the diameter of the embolizing particles44. On haematoxylin and eosin staining, the microinfarction from coronary microembolization appears as typical necrosis in dogs46,47, pigs46, mice45 and rats44,45. There is also evidence for apoptosis in the microinfarcted area shown by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)44,48–51 and increased expression of caspase 3, caspase 9 and Bax 2 (also known as apoptosis regulator BAX)43,52,53,54 and increased expression of Bax 2 (also known as apoptosis regulator BAX)43,52,53,54. However, the contribution of apoptosis to cell death from microinfarction is minor compared with that from necrosis. The microinfarct resulting from physical obstruction of a microvessel by inert microspheres is characterized by a profound inflammatory response leading to pyroptotic cell death52,54. Morphologically, oedema and neutrophil and macrophage infiltration occur around the microinfarct site in dogs44,46, pigs46,48, mice45 and rats44,45. The inflammatory response is also characterized by the increased expression of cytokines, such as tumour necrosis factor (TNF) in macrophages55 and cardiomyocytes44, as well as of interleukins55,56 and inducible nitric oxide synthase (iNOS)52 at the mRNA and protein levels. In rats, the activation of extracellular signal-regulated kinase 1 (ERK1) and ERK2 seems to be involved in initiating the inflammatory response57. Inflammation around microinfiltrates in pigs is associated with increased insulin-like growth factor 1 (IGF1) mRNA expression in infiltrating monocytes58, which is a potential start signal for an angiogenic response and for the promotion of collateral growth, as seen in
Fig. 1 | Repetitive intracoronary infusion of polystyrene microspheres in a dog.
The arrows along the top indicate infusion of 30,000 polystyrene microspheres of 42 μm in diameter. Coronary blood flow (red) is immediately reduced after infusion, recovers quickly and displays some reactive hyperaemia (exceeds baseline flow). Systolic myocardial wall thickening (blue) is also immediately reduced and recovers quickly but not back to baseline. After four infusions of microspheres, coronary blood flow is normal but systolic wall thickening has a cumulative deficit. Adapted with permission from ref. 48, APS.

A long-term model of coronary microembolization in dogs64. CT and MRI in pig models of coronary microembolization demonstrated not only a decrease in regional and global contractile function but also patchy perfusion defects, oedema and microinfarcts65–67.

Signal transduction of contractile dysfunction. Regional contractile function in microembolized myocardium follows a typical time course, with a decrease immediately after microembolization, followed by a partial recovery and then a subsequent deterioration over several hours, with a nadir at 6–12 h after the procedure68,69,70,71. A nadir in global LV function is also seen at around 12 h after microembolization72. The magnitude of contractile dysfunction exceeds that of acute ischaemia, reflecting the contribution of loss of viable contractile cardiomyocytes from microinfarction and, more importantly, contractile impairment in viable myocardium from the effect of negative inotropic inflammatory mediators (FIG. 3). With the intracoronary injection of microspheres in anaesthetized pigs, the total surface area of microperfusion defects was more closely correlated with LV contractile dysfunction than with the total volume of microperfusion defects on electron-beam CT72. This finding supports the notion that interaction with the surrounding myocardium and inflammation are more important for contractile dysfunction than the loss of viable tissue73.

The increased expression of TNF in macrophages and cardiomyocytes is central among the inflammatory mediators to exert negative inotropic effects on the microembolized myocardium45,53,61,63. Therefore, antibodies to TNF abrogate the progressive contractile dysfunction between 1 and 8 h after microembolization in anaesthetized dogs63. In anaesthetized pigs, nitric oxide is formed upstream of increased TNF expression and sphingosine is synthesized downstream of increased TNF expression48. As such, inhibition of nitric oxide formation by N-nitro-L-arginine methyl ester (L-NAME) or inhibition of sphingosine formation by N-oleoylphosphatidylcholine (NOE) abrogates progressive contractile dysfunction between 1 and 8 h after microembolization74. The ultimate effect of such inflammatory signal transduction is apparently the increased formation of reactive oxygen species (ROS), oxidative modification of contractile myofibrils75 and reduced Ca2+ responsiveness of the contractile machinery76. The causal role of ROS is supported by the prevention of myofibrillar oxidation and progressive contractile dysfunction by high-dose vitamin C77. In chronically instrumented dogs, regional contractile dysfunction has its nadir 4–12 h after coronary microembolization but recovers almost completely over 1 week68. Recovery is accelerated by intravenous methylprednisolone, further supporting the causal role of inflammation in the observed regional contractile dysfunction68. Although the causal role of inflammatory mediators in contractile dysfunction from coronary microembolization is obvious, we do not currently know the exact biochemical, cellular and subcellular source of each participating mediator nor the full sequence of signalling steps.

Several drugs attenuate contractile dysfunction but where and how they interact with signal transduction is unclear. Some of these drugs, including metoprolol63, nobiletin65, resveratrol66, breviscapine67, puerarin68, nicorandil69 and glycyrrhizin70 reduce markers of apoptosis (reduced caspase 3 activation and expression of p53 and Bax, reduced TUNEL staining) and activate classical cardioprotection pathways47 such as phosphoinositide 3-kinase (PI3K), protein kinase B (Akt) and glycogen synthase kinase 3β (GSK3β)49,50,71,72. Some of these drugs, including pyrroline dithiocarbamate45, glycyrrhizin70 and breviscapine67, also attenuate the expression of inflammatory cytokines45,50,69,73 or ROS68. In chronically instrumented pigs with coronary microembolization, long-term treatment with the angiotensin II receptor antagonist irbesartan improved both perfusion and contractile dysfunction53. Pretreatment with trimetazidine in anaesthetized pigs with coronary microembolization attenuated apoptosis (reduced activation of caspase 3 and caspase 9, reduced TUNEL staining) and global LV dysfunction (as shown on echocardiography) 12 h after coronary microembolization51.

Cardioprotection. Cardioprotection in its strictest sense refers to the reduction of infarct size that results from sustained and severe myocardial ischaemia and subsequent reperfusion by mechanical or pharmacological interventions74. Whereas microembolization induces patchy microinfarcts, the increased expression of TNF not only causes progressive contractile dysfunction45 but is also cardioprotective. In anaesthetized pigs, TNF expression was increased 6 h after coronary microembolization, and the infarct that resulted from 90 min of severe coronary hypoperfusion and 2 h of reperfusion was then reduced in size; this cardioprotection was abrogated by TNF antibodies75. While coronary microembolization per se apparently exerts cardioprotection under specific circumstances, it does not interfere with...
cardioprotection produced by ischaemic preconditioning or postconditioning. Conversely, in anaesthetized pigs, the immediate increase in coronary venous adenosine concentration associated with coronary microembolization did not result in infarct size reduction with the 90 min of severe myocardial ischaemia and 120 min of reperfusion that followed 10 min after microembolization. In addition, coronary microembolization did not interfere with cardioprotection from a true ischaemic preconditioning protocol (one 10-min cycle of severe ischaemia and 15 min of reperfusion), which was associated with a substantial increase in interstitial adenosine before 90 min of sustained ischaemia followed by 120 min of reperfusion, although coronary microembolization slightly increased infarct size. These findings contrast with the delayed cardioprotection associated with increased TNF expression described above. Collectively, these data suggest that coronary microembolization per se might induce some delayed protection but neither contributes to nor interferes with cardioprotection from pre-infarction angina. Almost the same is true for ischaemic postconditioning. The microinfarcts from coronary microembolization at early reperfusion following 90 min of severe myocardial ischaemia increased infarct size after 2 h of reperfusion in anaesthetized pigs. However, microembolization did not prevent infarct size reduction by an ischaemic postconditioning protocol (six cycles of 20 s of coronary occlusion and 20 s of reperfusion). Therefore, coronary microembolization, which is possibly associated with manipulation of the culprit lesion when applying an ischaemic postconditioning protocol, does not abrogate protection from postconditioning. Cardioprotective conditioning procedures are therefore still effective and could blunt deleterious infarct expansion from coronary microembolization.

**Coronary no-reflow.** Coronary no-reflow is the manifestation of coronary microvascular injury from sustained and severe myocardial ischaemia and reperfusion. No-reflow results from a number of pathomechanisms, including interstitial, endothelial and cardiomyocyte oedema, impaired vasomotion, leukocyte adherence and infiltration, stasis of blood elements, and capillary destruction and rupture. No-reflow can occur after sustained coronary occlusion and reperfusion in a previous virgin coronary vascular territory; therefore, it does not require physical obstruction by atherothrombotic material or the action of soluble factors released from upstream atherosclerotic lesions. Nevertheless, there are typical leukocyte–platelet aggregates and erythrocyte aggregates that obstruct the capillaries in the myocardium with no-reflow. Additionally, in a realistic clinical scenario of acute plaque rupture or erosion, there will be physical obstruction by atherothrombotic debris and microvascular dysfunction from prothrombotic, pro-inflammatory and vasoconstrictor soluble substances. Coronary microembolization with sodium laurate in rats induced microthrombi together with endothelial and cardiomyocyte injury, which were all attenuated by pretreatment with prostaglandin E1.

**Heart failure.** Progressive LV dysfunction following coronary microembolization with glass beads (400–600 µm diameter) in chronically instrumented dogs was first used as a preclinical heart failure model by Franciosa et al. Sabbah et al. then refined this dog model by using polystyrene microspheres (70–110 µm diameter) and a protocol of sequential microembolizations to establish stable heart failure characterized by patchy myocardial fibrosis and LV hypertrophy, apoptosis (demonstrated by DNA fragmentation and electron microscopy) and neurohumoral activation. With more limited coronary microembolization, heart failure (neurohumoral activation and volume expansion) with preserved ejection fraction could also be established. This model with characteristic features of LV dysfunction and neurohumoral activation was repeated in sheep. Sabbah et al. used coronary microembolization-induced heart failure in dogs to study the effects of several drugs. Metoprolol not only improved LV function but also attenuated apoptosis and endoplasmic reticulum stress and increased the expression of excitation–contraction coupling proteins. Metoprolol and enalapril also prevented progressive LV dilatation in this model. In a similar model of heart failure, in which microspheres of 45 µm diameter were used to induce coronary embolization in pigs, intracoronary cardiocyte-derived cell infusion reduced infarct size and collagen volume, increased myocyte number and capillary density, and improved regional and global LV function.
Animal experiments on coronary microembolization have strengths and limitations [BOX 1]. Collectively, however, these models are imperfect surrogates for the human clinical situation of acute or chronic coronary syndromes, with or without PCI.

Clinical coronary microembolization

The clinical presentation of coronary microembolization is unspecific, ranging from lack of symptoms and retrospective detection by chance to symptoms of an acute coronary syndrome. Coronary microembolization occurs spontaneously and as a result of cardiac, mostly coronary, interventions. Spontaneous coronary microembolization, typically symptomatic as an acute coronary syndrome, can be ascertained only at autopsy after sudden cardiac death. Increases in levels of biomarkers, such as creatine kinase or troponin (particularly with high-sensitivity assays), above the normal range reflect myocardial injury but are unspecific and fairly common in the general population. Such elevations in biomarkers become more frequent with increasing age and with the presence of other risk factors for atherosclerosis and are indicative of poor prognosis. The true contribution of coronary microembolization to an increase in biomarker levels cannot be distinguished from other causes, such as alternative forms of myocardial ischaemia, myocarditis, stroke, trauma and excessive exercise. Coronary microembolization is therefore more unequivocally identified in cardiac (notably coronary) interventions. Massive and often disastrous coronary embolization can arise from aortic or mitral valve endocarditis or iatrogenic valve interventions, atrial fibrillation or peripheral thrombosis through a patent foramen ovale. However, a coronary embolus is rarely the cause of an acute coronary syndrome and is seen in no more than 3% of patients undergoing catheterization for acute myocardial infarction (MI).

In the early reperfusion era, 80% of patients with acute MI who had undergone balloon angioplasty or thrombolysis and died within 3 weeks of the procedure had coronary emboli at autopsy. The embolium consisted of atherothrombotic material within the primary infarction, extending the infarction, inducing new infarction or involving non-infarcted myocardium. Microvascular obstruction/no-reflow is frequently seen on MRI in patients with reperfused acute STEMI, and microvascular obstruction is a determinant of patient prognosis, independent from and in addition to infarct size. However, MRI visualizes microvascular obstruction only in the infarcted tissue and not in the non-infarcted area at risk. MRI is usually performed within 1 week of reperfusion, and microvascular obstruction is typically identified at this point. However, the duration of microvascular obstruction and its distinction from scarring or angiogenesis on later MRI scans is unclear. Importantly, the contribution of coronary microembolization compared with other causes of microvascular obstruction, such as endothelial and interstitial oedema, vasosnstriction, leuocyte adherence, capillary destruction or haemorrhage, is impossible to quantify. We will therefore address only the clinical scenarios for which clear evidence for coronary microembolization exists.

To date, the recognition of coronary microembolization in patients with spontaneous acute coronary syndromes has not resulted in a protocol for risk stratification and management other than according to established guidelines. Coronary microembolization remains the conceptual ‘missing link’ between the culprit plaque lesion in the epicardial coronary artery (diagnosed by intravascular imaging) and the clinical presentation of NSTEMI with an increased level of troponin but without ST-segment elevation, with the consequent lack of an urgent need for PCI in many instances and an indication for proactive antiplatelet and anti-inflammatory treatment. In a sense, iatrogenically induced coronary microembolization during a coronary intervention can be viewed as a human model of a minor acute coronary syndrome and might facilitate its mechanistic understanding.

Fig. 3 | Coronary microembolization and its consequences. a | Rupture or erosion of an atherosclerotic plaque in an epicardial coronary artery releases particulate atherothrombotic debris and soluble substances into the coronary microcirculation. Debris causes physical obstruction of coronary microvessels, whereas soluble substances cause endothelial dysfunction, vasoconstriction and platelet aggregation. b | Microinfarcts occur in the myocardium accompanied by an inflammatory reaction, which impairs contractile function in adjacent surviving cardiomyocytes through signal transduction involving nitric oxide (NO), tumour necrosis factor (TNF), sphingosine, reactive oxygen species (ROS) and, ultimately, myofibrillar oxidation. Abs, antibody; l-NAME, Nω-nitro-l-arginine methyl ester; NOE, N-oleoylethanolamine.
Spontaneous coronary microembolization

Spontaneous coronary microembolization in the absence of PCI can be seen only at autopsy. In a systematic search for microthrombi in patients with heart disease, mostly of ischaemic origin, microthrombi rich in platelets and fibrin were seen in the coronary microcirculation, and platelet-rich microthrombi were more common in younger patients (aged <45 years) who had suffered sudden cardiac death than in older patients. The combination of epicardial plaque rupture or fissure together with microvascular atherothrombotic embolization in patients with ischaemic heart disease who had suffered sudden cardiac death was subsequently established through autopsy studies. The microemboli consisted of atherosclerotic plaque material, including cholesterol, platelet aggregates, platelet-leukocyte aggregates, hyalin and fibrin, and caused microinfarcts with an inflammatory response. These microinfarcts with inflammation were reminiscent of those seen in animal experiments with embolization induced by inert microspheres (discussed above). Subsequently, Schwartz et al. demonstrated that plaque erosion caused coronary microembolization more frequently than plaque rupture, microemboli were unrelated to stenosis severity of the culprit coronary artery and emboli were mostly seen in microvessels of <120 µm in diameter.

Periprocedural coronary microembolization

Biomarkers. Transient increases in serum levels of creatine kinase, creatine kinase-MB (CK-MB), and troponin I or troponin T after PCI are characteristic of periprocedural myocardial injury. Preferably, high-sensitivity cardiac troponin assays are used. According to the Fourth Universal Definition of Myocardial Infarction, an increase in cardiac troponin levels (measured by high-sensitivity assay) to above the 99th percentile upper reference limit in patients with normal baseline values or an increase by >20% in patients with elevated baseline values is defined as periprocedural myocardial injury (PMI). Major PMI and type 4a MI are defined by increases in cardiac troponin levels to above the fivefold 99th percentile upper reference limit and only such an increase carries an adverse prognosis for clinical outcome. However, the assessment of PMI from an elevation in troponin levels cannot distinguish between injury from side-branch occlusion and injury from distal coronary microembolization during PCI. The magnitude of biomarker release depends on the clinical situation of the patient (greater in patients with diabetes mellitus or chronic kidney disease), the nature of the vessel undergoing PCI (greater in saphenous vein grafts than in native coronary arteries and the type of procedure (greater with rotablation than simple stenting). The difference between elective and primary PCI in terms of resultant coronary microembolization is simply the iatrogenic versus spontaneous nature of its origin in the culprit lesion.

Imaging. Distal embolization can initially be visualized by angiography as an abrupt filling defect in a peripheral coronary branch. Imaging during PCI can identify the origin of the embolizing material in the epicardial coronary vascular wall by intravascular ultrasonography (IVUS) or optical coherence tomography (OCT). IVUS has greater penetration into the vascular wall than OCT and allows the different plaque components (that is, calcified, fatty, fibrotic and necrotic) to be distinguished by radiofrequency-based virtual histology. OCT has greater spatial resolution than IVUS and permits more detailed visualization of the endothelial layer and fibrous plaque cap. Therefore, OCT is particularly well suited to distinguishing between plaque rupture (a thin fibrous cap with rupture) and plaque erosion (a thick fibrous cap without rupture), both of which can result in coronary microembolization. Plaque volume on IVUS correlates with TNF release into the aspirate from an SVG during PCI, and the volume of the plaque necrotic core in native coronary arteries correlates with the release of creatine kinase and troponin into the systemic circulation following PCI. Showers of microemboli during elective PCI of native coronary arteries in patients with stable angina were visualized by intracoronary Doppler and correlated with the post-procedural elevation in serum troponin levels (Fig. 6). In patients with diabetes undergoing elective PCI, the Doppler-derived amount of microembolization correlated with the incidence of major adverse cardiovascular events (MACE) at 2-year follow-up. A typical finding indicating coronary microembolization, also reported

---

Box 1 Animal models of coronary microembolization

| All models | Strengths | Limitations |
|------------|-----------|-------------|
|            | • Controlled setting | • Non-human species |
|            | • Defined number and size of microemboli | • Young age |
|            | • Systematic post-mortem morphology and biochemistry | • No underlying atherosclerosis |
|            | • Doppler-derived measurement of microemboli | • Inert embolic material, except for autologous thrombi |

| Rodent | Strengths | Limitations |
|--------|-----------|-------------|
|        | • Inexpensive | • Cardiac anatomy different from that of humans |
|        | • Transgenic strains | • High heart rate |
|        |               | • Anaesthesia |

| Dog  | Strengths | Limitations |
|------|-----------|-------------|
|      | • Human-like anatomy and heart rate | • Expensive without anaesthesia |
|      | • Human-like model of chronic coronary syndromes | |

| Pig   | Strengths | Limitations |
|-------|-----------|-------------|
|       | • Human-like anatomy and heart rate | • Expensive |
|       | • Human-like model of myocardial infarction | |
in experimental studies using intracoronary injection of microspheres, is an increase in baseline coronary blood flow and a reduction in coronary reserve immediately after PCI. The reduction in coronary reserve correlated with postprocedural serum creatine kinase and troponin levels.

As in animal experiments with intracoronary injection of microspheres, local myocardial lesions resulting from microembolization in patients undergoing PCI can be visualized on postprocedural MRI. Quantification of patchy areas with delayed gadolinium contrast hyperenhancement correlated with postprocedural serum troponin levels and a reduction in plaque volume on IVUS. Areas with delayed hyperenhancement also had decreased local perfusion reserve, reflecting coronary microvascular obstruction. The amount of postprocedural hyperenhancement on MRI between 24 h and 6 days after PCI or coronary artery bypass graft surgery correlated with clinical outcome during a 3-year follow-up period. A disadvantage of MRI is that it cannot be used to distinguish between myocardial injury from coronary microembolization and other types of local injury such as side-branch occlusion.

**Interventional prevention and treatment.** In patients undergoing elective PCI, remote ischaemic preconditioning by one or more cycles of blood pressure cuff inflation and deflation on the arm reduced biomarker-defined PMI and the incidence of adverse events in several but not all studies. These studies differ from the experimental models discussed earlier in which local ischaemic preconditioning did not attenuate coronary microembolization. Whether remote ischaemic preconditioning stabilized the plaque or attenuated the myocardial injury from distal embolization is unclear. Possibly, remote ischaemic preconditioning induces the release of systemically circulating anti-inflammatory and cardioprotective substances, whereas local preconditioning does not. Reduced microvascular obstruction by remote ischaemic preconditioning in patients undergoing PCI for acute MI has also been reported but whether this benefit resulted from attenuated coronary microembolization or is a secondary effect of reduced infarct size is unknown.

Direct stenting reduced coronary microvascular resistance and tended to decrease postprocedural troponin release in patients with stable angina. In patients with acute MI, this procedure improved thrombolysis in myocardial infarction (TIMI) flow and reduced microvascular obstruction and infarct size on MRI in a subanalysis of a larger trial. The most likely mechanism for this reduction in microvascular obstruction is through the prevention of coronary microembolization from the culprit lesion.

The recognition of periprocedural coronary microembolization as a complication of PCI has stimulated the development of protection devices — filters or occlusion/aspiration systems to capture atherothrombotic debris, soluble substances or both that are released from the culprit lesion during PCI. The use of distal protection devices during elective PCI in native coronary arteries or SVGs was established as safe and feasible. Whether this benefit resulted from attenuated coronary microembolization is unknown.

**Fig. 4 | Imaging of plaque rupture and coronary microembolization.** a | Intravascular ultrasonography of a ruptured epicardial coronary atherosclerotic plaque after percutaneous coronary intervention (PCI). Arrows point to the ruptured cap and to the plaque, the debris from which is emptied into the coronary microcirculation. b | In the same vessel 2 mm distally, the thin cap is still intact but the plaque is empty. c | Optical coherence tomography of a thin and ruptured fibrous cap overlying an atherosclerotic plaque following PCI. d | Section of the same image at higher magnification. e | Intracoronary Doppler imaging of coronary blood flow velocity with high-intensity signals at baseline (arrow). f | After PCI, blood flow velocity is increased and more high-intensity signals (arrows) reflect showers of microemboli. Parts a and b adapted with permission from ref. Deutscher Aerzte-Verlag GmbH. Parts c and d adapted with permission from ref. EuroIntervention. Parts e and f adapted with permission from ref. Springer Nature Limited.
Fig. 5 | Angiography of PCI with a protection device and morphology of captured debris. a | Angiography of a saphenous vein graft (sternal wires from earlier coronary artery bypass graft surgery), with a stent balloon and a distal filter device. b | A photograph of the device with the captured debris. c | Haematoxylin and eosin-stained histology of particulate debris from the aspirate with amorphic lipid substance (ALS), a foam cell (FC), cholesterol crystals (arrows) and a thrombus (T). Parts a and b courtesy of Michael Haude (Rheinlandklinikum Neuss, Germany). Part c adapted with permission from REF. Springer Nature Limited.

in the AMEthyst trial in patients undergoing PCI of SVGs under protection with a novel filter device (AVE Interceptor; Medtronic) as compared with a balloon occlusion/aspiration device. In the PROXIMAL trial, no significant difference was seen in postprocedural creatine kinase level or in the primary clinical end point of death, MI and target-vessel revascularization between a proximal and a distal balloon occlusion/aspiration device in patients undergoing PCI of SVGs. Finally, in the CANARY trial, patients undergoing PCI of native coronary arteries under protection from a filter device had no benefit in terms of postprocedural troponin or creatine kinase levels. Therefore, evidence for the use of a protection device exists only in PCI of SVGs and essentially comes only from the results of the SAFER trial.

Several small, randomized, controlled clinical trials in patients with STEMI undergoing primary PCI have demonstrated the benefits of manual or device-based thrombus aspiration in terms of attenuated coronary microvascular and myocardial injury and clinical outcome (TABLE 1). In the large TOTAL trial of patients with STEMI, investigators reported better ST-segment resolution and less distal embolization on angiography from PCI with manual thrombus aspiration versus primary PCI alone. However, clinical outcome (cardiovascular death, re-infarction, cardiogenic shock or NYHA class IV heart failure) was not significantly improved, and a safety signal for stroke was reported with the use of thrombus aspiration. Patients with STEMI who presented late (≥12 and ≤48 h) after symptom onset also did not derive a benefit from thrombus aspiration. Therefore, in the 2018 European Society of Cardiology guidelines for the management of acute MI, routine use of thrombus aspiration is not recommended but can be considered in cases of large thrombus burden. By contrast, in patients with STEMI and culprit lesions that are particularly vulnerable to rupture (defined on IVUS), the combination of thrombus aspiration with a distal filter could be protective for the coronary microcirculation and improve clinical outcome. In the TATORT-NSTEMI trial, patients with NSTEMI and thrombus-containing culprit lesions had no better TIMI flow or reduced enzymatic infarct size with thrombus aspiration than with standard PCI, but a reduction in the primary composite end point of all-cause death, re-infarction and new heart failure with thrombus aspiration was reported. No guideline recommendation exists for the use of thrombus aspiration in patients undergoing PCI for NSTEMI but the positive clinical outcome data from the TATORT-NSTEMI trial suggest a greater potential for thrombus aspiration in NSTEMI than STEMI, indicating that coronary microembolization could have a greater role in NSTEMI than in STEMI.

Analysis of coronary aspirates. Filter and aspiration devices are used not only to protect the coronary microcirculation during PCI but also to retrieve particulate debris and soluble factors for analysis. Debris consists of plaque material, including foam cells and cholesterol crystals, and thrombus material rich in platelets and fibrin. The aspirate from stented native coronary arteries contains less particulate debris and the retrieved embolic material in native coronary arteries is smaller in volume and particle size than that from SVGs (plaque volume 135 ± 16 versus 176 ± 19 mm³; particulate debris 66 ± 10 versus 146 ± 23 mg). In other studies, patients with diabetes or chronic kidney disease had more particulate debris (and more calcium for the latter group of patients) in the aspirate from their stented SVGs than patients without these conditions. The coronary aspirate from native coronary arteries and SVGs can also contain microparticles derived from platelets and the endothelium, with no significant difference in their concentration between native coronary arteries and SVGs. In patients undergoing PCI for STEMI, increased numbers (as compared with peripheral arterial blood) of neutrophil–platelet aggregates were retrieved by thrombus aspiration. Notably, thrombi also contained high levels of neutrophil extracellular traps (NETs), which correlated with infarct size as determined by CK-MB levels and MRI. Again, in patients undergoing PCI for STEMI, increased levels of double-stranded DNA (as a surrogate for NETs) and IL-6 were retrieved by thromboaspiration from the culprit site and correlated with coronary microvascular obstruction on MRI 4–2 days later.

Soluble substances in the aspirate from stented native coronary arteries or SVGs have been determined biochemically or by functional bioassays. An increased release of tissue factor, endothelin, serotonin, thromboxane and TNE has been reported from the aspirate of stented coronary arteries and SVGs. The level of endothelin was greater in aspirate from native coronary arteries than from SVGs, with no significant differences in the other soluble substances between the two types of vessel. Aspiration from ruptured atherosclerotic plaque retrieved from
Table 1 | Coronary microvascular, myocardial and clinical outcomes in studies of manual or device-based thrombus aspiration

| Study reference | Study name (identifier)* | Clinical scenario | Intervention | n (placebo/intervention) | Coronary microvascular end points | Myocardial end points | Clinical outcomes |
|----------------|--------------------------|-------------------|--------------|--------------------------|----------------------------------|-----------------------|-------------------|
| Burzotta et al. (2005)152 | REMEDIA STEMI | STEMI | Manual aspiration | 49/50 | ↑ MBG | ↑ ST-segment resolution | = MACCE |
| Stone et al. (2005)153 | EMERALD STEMI | STEMI | Distal occlusion/aspiration | 249/252 | NA | = ST-segment resolution | = Infarct size on CT |
| Silva-Orrego et al. (2006)154 | DEAR-MI (NCT00257153) | STEMI | Aspiration device | 74/74 | ↑ MBG | ↑ ST-segment resolution | = MACE |
| Cura et al. (2007)155 | PREMIAR STEMI | STEMI | Distal filter | 70/70 | = MBG | = ST-segment resolution | = MACE |
| Muramatsu et al. (2007)156 | ASPARAGUS STEMI | STEMI | Distal occlusion/aspiration | 168/173 | = TIMI flow | = MBG | = ST-segment resolution | = CK-MB level |
| Kelbaek et al. (2008)157 | DEDICATION (NCT00192868) | STEMI | Distal filter | 314/312 | NA | = ST-segment resolution | = MACCE |
| Svilaas et al. (2009)158 | TAPAS (ISRCTN16716833) | STEMI | Manual aspiration | 536/535 | ↑ MBG | ↑ ST-segment resolution | = MACE |
| Tahk et al. (2009)159 | NA STEMI | STEMI | Distal occlusion/aspiration | 56/60 | ↑ TIMI flow | = CK-MB level | = MACE |
| Haeck et al. (2009)160 | PREPARE (ISRCTN71104460) | STEMI | Proximal occlusion/aspiration | 143/141 | = TIMI flow | = MBG | = ST-segment resolution | = CK-MB level |
| Sardella et al. (2009)161 | EXPIRA STEMI | STEMI | Aspiration device | 87/88 | ↑ MBG | ↑ ST-segment resolution | = MACE |
| Dudek et al. (2010)162 | PIHRATE (NCT00377650) | STEMI | Aspiration device | 96/100 | = TIMI flow | = MBG | = ST-segment resolution | = CK-MB level |
| Migliorini et al. (2010)163 | JETSTENT (NCT00275990) | STEMI | Distal jet-aspiration | 245/256 | = TIMI flow | = MBG | ↑ ST-segment resolution | = In-hospital mortality |
| Ciszewski et al. (2011)164 | NA STEMI | STEMI | Aspiration device | 70/67 | = TIMI flow | = MBG | ↑ Myocardial salvage index | = In-hospital mortality |
| De Carlo et al. (2012)165 | MUSTELA (NCT01472718) | STEMI | Manual or distal jet-aspiration | 104/104 | ↑ TIMI flow | ↑ MBG | ↑ ST-segment resolution | = MACCE |
| Stone et al. (2012)166 | INFUSE-AMI (NCT00976521) | STEMI | Manual aspiration | 223/229 | = TIMI flow | = MBG | = ST-segment resolution | = MACCE |
| Fröbert et al. (2013)167 | TASTE (NCT01093404) | STEMI | Manual aspiration | 3,623/3,621 | NA | NA | = Mortality | = MACCE |
Table 1 (cont.) | Coronary microvascular, myocardial and clinical outcomes in studies of manual or device-based thrombus aspiration

| Study reference | Study name (identifier) | Clinical scenario | Intervention | n (placebo/intervention) | Coronary microvascular end points | Myocardial end points | Clinical outcomes |
|-----------------|-------------------------|-------------------|--------------|--------------------------|----------------------------------|-----------------------|-------------------|
| Jolly et al. (2015) | TOTAL (NCT011490044) | STEMI | Manual aspiration | 5,030/5,033 | = TIMI flow | ↓ Distal embolization on angiography | = ST-segment resolution | = MACE<sup>a</sup> Safety signal for stroke |
| Desch et al. (2016) | (NCT01379248) | STEMI with late (≥12 h and ≤48 h) presentation | Manual aspiration | 55/56 | = TIMI flow | = MBG | = Infarct size on MRI | = MACCE |
| Hibi et al. (2018) | VAMPIRE3 (NCT01460966) | STEMI or NSTEMI and hypo-echoic plaque with deep ultrasound attenuation (length >5 mm) | Aspiration plus distal filter | 96/98 | ↑ TIMI flow | No-reflow on angiography<sup>b</sup> | = CK-MB level | ↓ In-hospital MACCE |
| Feistritzer et al. (2020) | TATORT (NCT01612312) | NSTEMI with thrombus-containing culprit lesion | Aspiration device | 217/215 | = TIMI flow | = MBG | = Troponin T level (high-sensitivity assay) | = MACE<sup>b</sup> |

<sup>a</sup> On placebo, significant increase; ↓, significant decrease; =, no significant change; CK-MB, creatine kinase-MB; ISRCTN, International Standard Randomized Controlled Trials Number; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiac events; MBG, myocardial blush grade; MVO, microvascular obstruction; NA, not applicable; NCT, national clinical trial; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction. If available. <sup>b</sup>Primary study end points.

Patients undergoing primary PCI also had increased concentrations of IL-6 and serum amyloid A<sup>18</sup>. In functional bioassays using rat isolated mesenteric arteries, the aspirate from stented SVGs induced profound vasoconstriction<sup>180,182</sup>, which was mediated by serotonin and thromboxane receptors. Accordingly, blockade of 5-HT (serotonin) and thromboxane receptors abrogated the intense vasoconstriction, as did more specific vasodilatation by verapamil and less so by nitroprusside<sup>180</sup>. In patients with severely stenotic SVGs, the release of TNF into SVG aspirate correlated with a reduction in plaque volume (measured by IVUS) and with the development of restenosis (measured by angiography) after 6 months<sup>120</sup> and a correlation between TNF release and restenosis was also seen in patients with diabetes<sup>131</sup>.

In the OPTICO-ACS trial<sup>183</sup>, 170 consecutive patients undergoing PCI for an acute coronary syndrome had an increased concentration of CD8<sup>+</sup> lymphocytes and cytotoxic effector molecules (granzyme A, granulysin and perforin) and a lower concentration of TNF in the aspirate distal to the culprit lesion when characterized by OCT as plaque erosion than when characterized as plaque rupture.

Collectively, these data from analyses of coronary aspirate support the notion that active prothrombotic, pro-inflammatory and vasoconstrictor substances are a major cause of microvascular and myocardial injury from microembolization. The exact cellular (vascular and inflammatory cells within the atherosclerotic plaque, intravascular cells in the thrombotic material) and biochemical sources of these substances are still unclear. Given that the myocardial perfusion territory of a vessel with physical obstruction by atherosclerotic debris can probably not be rescued from infarction, greater attention should be directed to the pathogenetic soluble factors and their pharmacological antagonism.

### Prevention and treatment

Herrmann et al. were the first to report that patients who were statin naive undergoing elective PCI had greater increases in postprocedural serum creatine kinase levels than patients treated with statins<sup>184</sup>, and this finding was subsequently confirmed<sup>185</sup>. Whether long-term statin treatment improved plaque stability<sup>186</sup> and prevented coronary microembolization or instead attenuated myocardial injury from coronary microembolization was unclear. Indeed, acute pretreatment with statins of patients who were statin naive before elective PCI also decreased postprocedural serum creatine kinase and troponin elevations<sup>187,188</sup>. Attenuation of intercellular adhesion molecule 1 (ICAM1) and E-selectin concentrations in the plasma reflected reduced endothelial inflammation but, again, whether this finding reflected proximal coronary plaque stabilization or reduced distal microvascular and myocardial injury was uncertain<sup>189</sup>. In any event, acute pretreatment with statins just before PCI also reduced the rate of postprocedural MACE<sup>190</sup>. The observation of reduced release of serum creatine kinase and troponin and a reduced incidence of MACE with statin reload a few hours before elective PCI<sup>191,192</sup> supports the notion that statins also attenuate distal microvascular and myocardial injury. Less coronary microvascular and myocardial injury was also seen in mouse isolated hearts with ischaemia–reperfusion<sup>193,194</sup> and in anaesthetized pigs with coronary occlusion and reperfusion<sup>195</sup>.

<sup>18</sup>↑, significant increase; ↓, significant decrease; =, no significant change; CK-MB, creatine kinase-MB; ISRCTN, International Standard Randomized Controlled Trials Number; MACCE, major adverse cardiac and cerebrovascular events; MACE, major adverse cardiac events; MBG, myocardial blush grade; MVO, microvascular obstruction; NA, not applicable; NCT, national clinical trial; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction. If available. <sup>191</sup>Primary study end points.
Antiplatelet and antithrombotic agents are routinely used before any cardiac catheterization and PCI procedure and are standard and guideline-recommended treatments for any acute coronary syndrome. Therefore, evaluating the effect of antiplatelet agents on periprocedural coronary microembolization is impossible. However, in the ARMYDA-2 trial, an increased loading dose of clopidogrel (600 mg) attenuated the increases in serum CK-MB, troponin I, and myoglobin levels more than the standard dose (300 mg). Antiplatelet agents not only reduce intravascular formation and embolization of platelet aggregates but also have direct cardioprotective effects to attenuate myocardial injury. However, not all antiplatelet agents are equal. In the ISAR-REACT 5 trial, the regimen with prasugrel was superior to that with ticagrelor in reducing the composite end point of death, MI or stroke in patients with acute coronary syndromes after 1 year. The reasons for the difference between the two platelet inhibitors in their effects on coronary microembolization are not understood. The INFUSE-AMI trial demonstrated that intracoronary abciximab (a glycoprotein IIb/IIIa inhibitor) reduced microvascular obstruction and infarct size in patients undergoing primary PCI for MI. Routine administration of glycoprotein IIb/IIIa inhibitors resulted in better TIMI flow, reduced ischemic events and reduced mortality in patients with reperfused STEMI in a large meta-analysis of 8,585 patients. However, most of the trials included in this analysis were conducted before the era of prasugrel and ticagrelor. By contrast, fibrinolysis with intracoronary infusion of alteplase did not attenuate microvascular obstruction in patients with STEMI undergoing PCI within 6 h of symptom onset. Therefore, whether intracoronary fibrinolysis confers additional benefit to PCI and antiplatelet agents in the attenuation of coronary microvascular obstruction is still unclear and under investigation.

The use of coronary vasodilators, including adenosine, nitroprusside and verapamil, in the attenuation of coronary microvascular obstruction has not been convincing. The effects of adenosine on microvascular obstruction per se and on clinical benefit are ambiguous. The ex vivo vasoconstrictor effects of coronary aspirate from SVGs, when analysed in isolated rat mesenteric arteries, were attenuated to a greater extent by verapamil than by nitroprusside, whereas adenosine had a negligible effect. Verapamil also improved TIMI flow to a greater extent than nitroglycerin in patients undergoing PCI of degenerated SVGs.

Anti-inflammatory interventions to prevent and treat coronary microembolization warrant further study. The CANTOS trial addressed the pathogenetic role of IL-1β in patients with previous MI and increased plasma C-reactive protein (CRP) concentrations. A reduced rate of cardiovascular events, including unstable angina requiring urgent revascularization, was reported with subcutaneous administration of the human monoclonal IL-1β-neutralizing antibody canakinumab. Mechanistically, canakinumab might blunt the IL-1β-associated increase in NETs and levels of tissue factor found in patients with MI and increased plasma CRP concentration. Patients who received canakinumab in the CANTOS trial had a reduced cardiovascular event rate associated with reductions in plasma IL-6 concentrations. Long-term antagonism of IL-1β and IL-6 could stabilize epicardial atherosclerotic plaques and prevent their eventual rupture or erosion. In the more acute situation of an interventional procedure for a stable or acute coronary syndrome, in which coronary microembolization can occur and anti-inflammatory action in the coronary microcirculation might be important, the benefit of interleukin receptor antagonists and other anti-inflammatory drugs is less clear. Indeed, the monoclonal IL-1β receptor antagonist anakinra given subcutaneously to patients within 48 h of PCI for NSTEMI reduced plasma CRP levels but did not provide clinical benefit. By contrast, the IL-6 receptor antagonist tocilizumab given intravenously in patients undergoing PCI for NSTEMI reduced plasma concentrations of both CRP and troponin T (measured by high-sensitivity assay). In addition, reduced myocardial injury was seen in patients who were resuscitated after cardiac arrest. Notably, in patients with STEMI, intravenous tocilizumab during PCI reduced microvascular obstruction and improved the salvage index on MRI 3–7 days after the procedure, supporting the notion that inflammatory microembolization is a contributing factor in microvascular obstruction. However, the protection by tocilizumab was significant but small in magnitude, and no outcome data for tocilizumab in patients with NSTEMI or STEMI are yet available. In the SELECT-ACS trial, preprocedural infusion of inclacumab (a monoclonal antibody to the endothelial adhesion molecule P-selectin) reduced circulating P-selectin and troponin I concentrations in patients with NSTEMI undergoing angiography and ad hoc PCI. Colchicine given orally to patients with acute coronary syndrome within hours to days of PCI reduced plasma CRP and interleukin concentrations in some but not all studies. Colchicine reduced biomarkers of myocardial injury in some but not all studies. Therefore, the clinical benefit of...
Coronary microembolization in COVID-19

Coronavirus disease 2019 (COVID-19) is characterized by endothelial infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with consequent endothelial injury and systemic thrombo-inflammation involving cytokine release, increased platelet activation and platelet-leukocyte aggregation. The theory that IL-6 has a pathogenetic role in COVID-19 is supported by the finding that the IL-6 receptor antagonist tocilizumab (with aspirin or a P2Y<sub>12</sub> inhibitor) blunted platelet activation after ex vivo exposure of platelets and leukocytes from healthy volunteers to COVID-19 plasma. These data support the notion that inhibition of IL-6 not only stabilizes atherosclerotic plaques but also attenuates the downstream effects of platelet aggregation and inflammation. Thromboembolization, particularly in patients with pre-existing endothelial dysfunction, is a typical complication of COVID-19 and could also affect the coronary circulation, even in the absence of pre-existing coronary artery disease. Indeed, human coronary endothelial cells are particularly sensitive to SARS-CoV-2 infection. Thrombi rich in fibrin, platelets and leukocytes in the coronary microcirculation were seen at autopsy in 10–20% of patients who had died from COVID-19 [REFS 226, 227]. In a pathology analysis, intracoronary microthrombi, which were particularly rich in fibrin and complement, were seen in 35% of patients who had died from COVID-19 and had evidence of myocardial necrosis, irrespective of whether or not they had pre-existing coronary artery disease [REF 228]. In patients with STEMI with or without COVID-19, thromboaspiration retrieved thrombi containing fibrin, leukocytes and NETs [REF 229]. In patients with COVID-19, no plaque fragments were observed and a greater density of NETs was present in the aspirate than in patients without COVID-19 [REF 230].

Conclusions

The secular trends in a shift from plaque rupture to plaque erosion as the trigger event and from STEMI to NSTEMI in clinical presentation suggest the increasing pathophysiological importance of distal embolization in the coronary circulation. Indeed, coronary microemboli are more frequently seen at autopsy after plaque erosion than after plaque rupture. There is certainly no stoichiometric one-to-one relationship between plaque erosion, coronary microembolization and NSTEMI. Nevertheless, the observed association advocates for greater awareness of coronary microembolization in the assessment and treatment of these patients. Prevention of spontaneous coronary microembolization entails the use of all anti-atherosclerotic medications. Statins and inhibitors of platelet aggregation are effective for the prevention of coronary microembolization and to treat its consequences. Studies of protection devices to prevent procedural coronary microembolization have been largely disappointing, and their use is limited to situations of large atherothrombotic plaque burden in SVGs.

Future therapies should target the interaction between inflammation and platelet aggregation at the epicardial culprit lesion and in the coronary microcirculation. Further analyses of coronary aspirate or transcoronary gradients from patients with acute coronary syndromes could uncover more detail on the pathophysiological mechanisms of coronary microembolization and help to develop targeted therapies.

Published online 16 November 2021

1. Falk, E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br. Heart J. 50, 127–154 (1983).
2. Davies, M. J. & Thomas, A. C. Plateau fissuring: the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br. Heart J. 53, 363–373 (1985).
3. Falk, E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 71, 699–708 (1985).
4. El-Maraghi, N. & Genton, E. The relevance of platelet and fibrin thromboembolism of the coronary microcirculation, with special reference to sudden cardiac death. Circulation 62, 936–944 (1980).
5. Davies, M. J., Thomas, A. C., Knappman, P. A. & Hangartner, J. R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischaemic cardiac death. Circulation 73, 418–427 (1986).
6. Frisk, R. J., Rooney P. A., Trowbridge, J. O. & Rose, J. P. Coronary thrombosis and platelet/fibrin microemboli in death associated with acute myocardial infarction. Br. Heart J. 59, 196–200 (1988).
7. Folts, J. D., Gallagher, K. & Rowe, G. G. Blood flow reductions in stenosed canine coronary arteries: vasoospasm or platelet aggregation? Circulation 65, 248–255 (1985).
8. Ettedgui, J. F. et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J. Clin. Invest. 84, 18–27 (1989).
9. Golino, P., Buja, M., Sheng-Kun, Y., McNatt, J. & Willerson, J. T. Failure of nitroglycerin and diltiazem to reduce platelet-mediated vasoconstriction in dogs with coronary artery stenosis and endothelial injury: further evidence for thromboxane A2 and serotonin as mediators of coronary artery vasoconstriction in vivo. J. Am. Coll. Cardiol. 15, 718–726 (1990).
10. Folts, J. D. Deleterious hemodynamic effects of thrombotic/embolic materials on the distal myocardial vasculature. Cardiovasc. Res. 42, 6–7 (1999).
11. Erdel, V. & Heusch, G. Brief review: coronary microembolization. J. Am. Coll. Cardiol. 36, 22–24 (2000).
12. Topol, E. J. & Yadav, J. S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101, 570–580 (2000).
13. Gregorini, L., Marco, J. & Heusch, G. Peri-interventional coronary vasomotion. J. Mol. Cell. Cardiol. 52, 885–889 (2012).
14. Libby, P., Pasterkamp, G., Crea, F. & Jang, I. K. Reassessing the mechanisms of acute coronary syndromes. Circ. Res. 124, 150–160 (2019).
15. Fahed, A. C. & Jang, I. K. Platelet erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions. Nat. Rev. Cardiol. 18, 724–734 (2021).
16. Kolte, D., Libby, P. & Jang, I. K. New insights into plaque erosion as a mechanism of acute coronary syndromes. JAMA 325, 1045–1046 (2021).
17. Libby, P. The changing landscape of atherosclerosis. Nature 592, 524–533 (2021).
18. Payurat, E. et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FASTMI Program [French Registry of Acute STElevation or Non-ST-elevation Myocardial Infarction] 1995 to 2015. Circulation 14, 1908–1919 (2017).
19. Schwartz, R. S. et al. Microemboli and microvascular obstruction in acute coronary thrombosis and sudden coronary death relation to epicardial plaque histopathology. J. Am. Coll. Cardiol. 54, 2167–2173 (2009).
20. Partida, R. A., Libby, P., Crea, F. & Jang, I. K. Plaque erosion: a new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes. Eur. Heart J. 39, 2070–2076 (2018).
21. Collet, J. P. et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 42, 1289–1367 (2021).
22. Hamburgh, W. W., Priest, W. S., Bettsman, R. B. & Howard, H. C. Experimental coronary embolism. Am. J. Med. Sci. 171, 168–185 (1926).
23. Agress, C. M. et al. Protracted shock in the closed-chest dog following coronary embolization with graded microspheres. Am. J. Physiol. 170, 536–549 (1952).
24. Bing, R. J., Castellanos, A., Gradell, E., Lupton, C. & Siegel, A. Experimental myocardial infarction: circulatory biochemical and pathologic changes. Am. J. Med. Sci. 232, 553–556 (1956).
25. Marcus, E. et al. The production of myocardial infarction. Chronic coronary insufficiency and chronic coronary heart disease in the dog. Acta Cardiol. 13, 190–198 (1958).
26. Guzman, S. V., Swenson, E. & Jones, M. Inter-coronary reflux. Demonstration by coronary angiography. Circ. Res. 10, 739–745 (1962).
Agess, C. M., Rosenberg, M. J., Binder, M. J., Schneiderman, A. & Clark, W. G. Blood volume changes in protracted shock resulting from experimental myocardial infarction. *Am. J. Physiol.*** 166, 603–606 (1951).

50. Heusch, G. The regional myocardial flow-function relationship: a framework for an understanding of acute ischemic and corona microembolization. *Circ. Res.* 112, 1555–1557 (2013).

51. Arras, M. et al. Tumor necrosis factor-a is expressed by macrophages following coronary microembolization and is antagonized by cyclosporine. *Basic Res. Cardiol.* 93, 97–107 (1998).

52. Su, G. et al. Effect of metoprolol on myocardial apoptosis and cardiac function after coronary microembolization in rats. *Exp. Clin. Cardiol.* 18, 161–185 (2013).

53. Liu, Y. C., Li, Q., Gu, Q., Liu, T. & Tang, Z. L. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a swine model of coronary microembolization. *Cardiology* 130, 150–156 (2015).

54. Mao, Q., Liang, X., Wu, Y. & Yu, N. Nobiletin protects against myocardial injury and myocardial apoptosis following coronary microembolization via activating PI3K/Akt pathway in in vivo study. *Naunyn Schmiedeberg’s Arch. Pharmacol.* 592, 1121–1130 (2019).

55. Mao, Q., Li, Q. & Lu, W. Overexpression of nNOS attenuates cardiomyocyte apoptosis in rats induced by coronary microembolization through SIRT1-mediated deacetylation of p53. *Cardiovasc. Pharmacol. Ther.* 24, 551–558 (2019).

56. Yuan, Y., Li, B., Peng, W. & Xu, Z. Protective effect of glycyrrhetinic acid on myocardial microembolization-induced myocardial dysfunction in rats. *Pharmacol. Res.* 79, e001711 (2021).

57. Chen, Z. Q. et al. miR-200b-5p attenuates coronary microembolization-induced myocardial injury in rats by inhibiting TNF/IPLR5-mediated cardiomyocyte pyroptosis. *Front. Cardiovasc. Med.* 6, 983527 (2020).

58. Zhou, Y. et al. Overexpression of IncRNA TUC1 alleviates NLRP3 inflammasome-mediated myocardial injury following the miR-186-SpunX axis in coronary microembolization-induced myocardial damage. *Front. Immunol.* 12, 673598 (2021).

59. Hori, M. et al. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. *Circulation* 84, 820–840 (1991).

60. Saed, M. et al. Evaluation of the acute effects of distal coronary microembolization using multilabeled microspheres. *Circulation* 110, 945–952 (2000).

61. Carlson, M., Wilson, M., Martin, A. J. & Saeed, M. Myocardial infarction after coronary microembolization in swine. *MR imaging characterization. Radiology* 250, 705–713 (2009).

62. Dörge, H. et al. Characterization of cardiomyocyte apoptosis and dedifferentiation in infarct border zones. *Eur. J. Heart J.* 23, 849–857 (2002).

63. Carlsson, M. et al. A novel mouse model of coronary microembolization. *Clin. Med. J. 129, 2951–2957 (2016).

64. Li, L., Zhao, X., Lu, Y., Huang, W. & Wen, W. Altered expression of pro- and anti-inflammatory cytokines is associated with reduced cardiac function in rats following coronary microembolization. *Mic. Cell. Biochem.* 342, 185–190 (2010).

65. Li, S. et al. Blockade of NF-kappaB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and myocardial dysfunction following coronary microembolization induced by homologous microthrombi in rats. *Basic Res. Cardiol.* 105, 69–73 (2010).

66. Gallagher, K. P., Osaka, K., Kemper, W. S. & Ross, J. Jr. Cyclical coronary flow reductions in conscious dogs equipped with amenable producers to produce coronary arterial microembolization. *Circulation* 80, 100–106 (1985).

67. Barrabés, J. A. et al. Dynamic intracoronary thrombosis does not cause significant downstream platelet embolisation. *Cardiovasc. Res.* 47, 265–273 (2000).

68. Skysschally, A., Schulz, R., Ebeler, R. & Heusch, G. Reduced coronary and inotropic reserves with coronary microembolization. *Am. J. Physiol. Heart Circ. Physiol.*** 282, H611–H614 (2002).

69. Reddy, C. M., Rosenburg, M. J., Binder, M. J., Schneiderman, A. & Clark, W. G. Blood volume changes in protracted shock resulting from experimental myocardial infarction. *Am. J. Physiol.* 166, 603–606 (1951).

70. Heusch, G. The regional myocardial flow-function relationship: a framework for an understanding of acute ischemic and coronary microembolization. *Circ. Res.* 112, 1555–1557 (2013).

71. Arras, M. et al. Tumor necrosis factor-a is expressed by macrophages following coronary microembolization and is antagonized by cyclosporine. *Basic Res. Cardiol.* 93, 97–107 (1998).

72. Su, G. et al. Effect of metoprolol on myocardial apoptosis and cardiac function after coronary microembolization in rats. *Exp. Clin. Cardiol.* 18, 161–185 (2013).

73. Liu, Y. C., Li, Q., Gu, Q., Liu, T. & Tang, Z. L. Trimetazidine pretreatment inhibits myocardial apoptosis and improves cardiac function in a swine model of coronary microembolization. *Cardiology* 130, 150–156 (2015).

74. Mao, Q., Liang, X., Wu, Y. & Yu, N. Nobiletin protects against myocardial injury and myocardial apoptosis following coronary microembolization via activating PI3K/Akt pathway in in vivo study. *Naunyn Schmiedeberg’s Arch. Pharmacol.* 592, 1121–1130 (2019).

75. Mao, Q., Li, Q. & Lu, W. Overexpression of nNOS attenuates cardiomyocyte apoptosis in rats induced by coronary microembolization through SIRT1-mediated deacetylation of p53. *Cardiovasc. Pharmacol. Ther.* 24, 551–558 (2019).

76. Yuan, Y., Li, B., Peng, W. & Xu, Z. Protective effect of glycyrrhetinic acid on myocardial microembolization-induced myocardial dysfunction in rats. *Pharmacol. Res.* 79, e001711 (2021).

77. Chen, Z. Q. et al. miR-200b-5p attenuates coronary microembolization-induced myocardial injury in rats by inhibiting TNF/IPLR5-mediated cardiomyocyte pyroptosis. *Front. Cardiovasc. Med.* 6, 983527 (2020).

78. Zhou, Y. et al. Overexpression of IncRNA TUC1 alleviates NLRP3 inflammasome-mediated myocardial injury following the miR-186-SpunX axis in coronary microembolization-induced myocardial damage. *Front. Immunol.* 12, 673598 (2021).

79. Hori, M. et al. Role of oxygen-derived free radicals in myocardial edema and ischemia in coronary microvascular embolization. *Circulation* 84, 820–840 (1991).

80. Saed, M. et al. Evaluation of the acute effects of distal coronary microembolization using multilabeled microspheres. *Circulation* 110, 945–952 (2000).

81. Carlson, M., Wilson, M., Martin, A. J. & Saeed, M. Myocardial infarction after coronary microembolization in swine. *MR imaging characterization. Radiology* 250, 705–713 (2009).

82. Dörge, H. et al. Characterization of cardiomyocyte apoptosis and dedifferentiation in infarct border zones. *Eur. J. Heart J.* 23, 849–857 (2002).

83. Carlsson, M. et al. A novel mouse model of coronary microembolization. *Clin. Med. J. 129, 2951–2957 (2016).*
Ikram, H. et al. An ovine model of acute myocardial infarction and chronic left ventricular dysfunction. *Angiology* 48, 679–688 (1997).

George, I., Sabbah, H. N., Xu, K., Wang, N. & Wang, J. β-Blocker treatment reduces endoplasmic reticulum stress and normalizes calcium handling in a coronary embolization model of heart failure in pigs. *Circulation* 109, 447–455 (2001).

Sabbah, H. N. et al. Chronic therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure. *J. Am. Coll. Cardiol.* 36, 1698–1705 (2000).

Suzuki, G., Young, R. F., Leiker, M. M. & Suzuki, T. Heart-derived stem cells in miniature swine with coronary artery bypass grafts. Novel ischaemic cardiomyopathy model to assess the efficacy of cell-based therapy. *Stem Cell Int.* 2016, 6940195 (2016).

Leach, I. H., Blundell, J. W., Rowley, J. M. & Park, K. C., Gaze, D. C., Collinson, P. O. & Marber, M. S. Association between microvascular obstruction and adverse events following primary percutaneous coronary interventions: a cardiac magnetic resonance imaging study. *Arch. Cardiovasc. Dis.* 103, S100–S109 (2010).

Raphael, C. E. et al. Coronary embolus: An underappreciated cause of acute coronary syndromes. *J. Am. Coll. Cardiol.* 61, 172–180 (2013).

Saber, R. S. et al. Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 33 cases of out-of-hospital death. *Eur. Heart J.* 16, 1181–1185 (1995).

Haller, P. M., Beer, B. N., Tenkin, A. M., Blankenberg, S. & Neumann, J. T. Role of cardiac biomarkers in epidemiology and risk outcomes. *Clin. Chem.* 67, 96–102 (2021).

Park, K. C., Gaze, D. C., Collinson, P. O. & Marber, M. S. Coronary troponins: from myocardial infarction to chronic disease. *Cardiosci. Rev.* 113, 1708–1718 (2017).

Boese, D. et al. The impact of stenting during saphenous vein bypass graft restenosis risk in diabetic canines. *J. Am. Coll. Cardiol.* 70, 303–312 (2012).

Hildebrandt, H. A. et al. Fingerprints of periprocedural myocardial infarction: a cardiac magnetic resonance imaging study. *Circulation* 135, E339–E355 (2017).

Hori, M. et al. Adenosine- induced hyperemia attenuates cardiomyocyte apoptosis in dogs with chronic kidney disease: more plaque calcification and necrosis, but less vasococontractor potential. *Basic Res. Cardiol.* 107, 503 (2012).

Kleinbongard, P. et al. Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris. *Am. J. Physiol. Heart Circ. Physiol.* 305, H1222–H1229 (2013).

Grube, E. et al. Embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. *Circulation* 121, 1392–1401 (2010).

Kini, A. et al. Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with distinct protection devices. *Catheter Cardiovasc. Interv.* 48, 123–129 (1999).

Hong, M. K. et al. Clinical significance of distal embolization after transluminal extraction athereectomy in patients with chronic ischemic cardiomyopathy. *Am. J. Heart* 127, 1496–1503 (1994).

Henriques, J. P. S. et al. Incidence and clinical significance of distal embolization during primary angioplasty for acute myocardial infarction. *Eur. Heart J.* 23, 1112–1117 (2002).

Boese, D. et al. Impact of atherosclerotic plaque composition on coronary microembolization during percutaneous coronary interventions. *Basic Res. Cardiol.* 103, 587–597 (2008).

Clemmensen, S. E. et al. Transduction of remote ischemic preconditioning with species-specific myocardial signal transduction by reperfusion injury salvage kinase and survival activating factor enhancement pathways. *Circ. Res.* 117, 279–288 (2015).

Lieder, H. R. et al. Vago-splenial axis in signal transduction of remote ischemic preconditioning in pigs and rats. *Circ. Res.* 118, 1113–1125 (2018).

Crim, G. et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safety reduces infarct size in anterior myocardial infarction: a randomized controlled trial. *JACC Cardiovasc. Interv.* 6, 1055–1065 (2012).

Eitel, I. et al. Cardioprotection by combined intrahospital remote ischaemic preconditioning and postconditioning in ST-segment elevation myocardial infarction: the randomized LIPC PCI trial. *Eur. Heart J.* 36, 3049–3057 (2015).

White, S. K. et al. Remote ischemic conditioning reduces myocardial ischemic injury in patients with ST-segment elevation myocardial infarction. *JACC Cardiovasc. Interv.* 8, 178–188 (2015).

Liu, C. et al. Remote Ischemic Postconditioning in ST- elevation myocardial infarction patients undergoing primary percutaneous coronary intervention. *Acta Cardiol.* 71, 596–603 (2016).

Cunset, T. et al. Direct stenting for stenting angina pectoris is associated with reduced periprocedural microcatheter injury compared with stenting after pre- dilatation. *J. Am. Coll. Cardiol.* 51, 1060–1065 (2008).

Loubeyre, C. et al. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute coronary syndrome. *Arch. Cardiovasc. Dis.* 103, 667–671 (2010).

Saad, M. et al. Impact of direct stenting on myocardial injury assessed by a cardiac transduction of remote ischemic imaging and prognosis in ST-Elevation myocardial infraction. *Int. J. Cardiol.* 288, 89–92 (2019).

Popma, J. J. et al. Initial clinical experience with distal protection using the FilterWire in patients undergoing coronary artery and saphenous vein graft percutaneous intervention. *Catheter. Cardiovasc. Interv.* 67, 125–132 (2005).

Anglelli, A. et al. Distal protection with a filter device during coronary stenting in patients with stable and acute coronary angiina. *Circulation* 111, 15–21 (2004).

Limbrufo, U. et al. Distal embolization during primary angioplasty: histopathologic features and predictability. *Am. Heart J.* 150, 102–108 (2005).

Baim, D. S. et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. *Circulation* 105, 1285–1290 (2002).

Stone, G. W. et al. Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts. *Circulation* 108, 546–553 (2003).

Kerenakes, D. J. et al. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions. *JACC Cardiovasc. Interv.* 1, 248–257 (2008).

Mauri, L. et al. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis Embolic Protection System: a randomized, prospective, multicenter clinical trial. *J. Am. Coll. Cardiol.* 64, 1640–1649 (2014).

Stone, G. W. et al. Plaque characterization to inform the prediction and prevention of periprocedural myocardial infarction following percutaneous coronary intervention: the CANARY Trial (Coronary Assessment Near-infrared of Atherothrombotic Rupture-protection and Assessment of Necrosis). *Circ. Res.* 117, 950–956 (2015).

Buzzotta, F. et al. Manual thrombus-aspiration improves myocardial reperfusion. The randomized evaluation of the effect of mechanical reduction of
distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J. Am. Coll. Cardiol. 46, 371–376 (2005).

153. Stone, G. W. et al. Distal microcirculatory protection during primary percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA 293, 1065–1072 (2005).

154. Silva-Orrego, P. et al. Thrombosis aspiration before primary angioplasty improves myocardial reperfusion in STEMI patients: the DEAR-MI (Dethrombosis to Enhance Acute Reperfusion in Myocardial Infarction) study. J. Am. Coll. Cardiol. 54, 1552–1559 (2009).

155. Cusi, F. A randomized comparison of distal embolization in high-risk patients with acute ST-segment elevation myocardial infarction (PREMIAR). Am. J. Cardiol. 99, 1057 (2007).

156. Muramatsu, T. et al. Comparison of myocardial perfusion by distal stent placement before and after primary stenting for acute myocardial infarction: angiographic and clinical results of a randomized controlled trial. Catheter. Cardiovasc. Interv. 70, 677–682 (2007).

157. Keelha, H. et al. Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary revascularization: the drug elution and distal protection in ST-Elevation myocardial infarction (DEDEST) trial. J. Am. Coll. Cardiol. 51, 899–905 (2008).

158. Svilaas, T. et al. Thrombus aspiration during primary percutaneous coronary intervention. N. Engl. J. Med. 358, 557–567 (2008).

159. Takhi, S. J. et al. Distal protection device protects microvascular integrity during primary percutaneous intervention in acute myocardial infarction: a prospective, randomized, multicenter trial. Int. J. Cardiol. 104, 173–178 (2005).

160. Haack, J. D. E. et al. Randomization of primary percutaneous coronary intervention with combined proximal embolic protection and thrombectomy versus percutaneous coronary revascularization alone in ST-segment elevation myocardial infarction: the PREPARE (Proximal Embolic Protection to Reduce Adverse Events during Coronary Stenting and Resolution of ST-Elevation) Study. JACC Cardiovasc. Interv. 2, 954–963 (2009).

161. Sardella, G. et al. Thrombus aspiration during primary percutaneous coronary intervention improves myocardial reperfusion and reduces infarct size: the EXCITE study. JACC Cardiovasc. Interv. 1, 307–315 (2008).

162. Duke, D. et al. Thrombectomy followed by direct stenting: a novel strategy of primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results of the Trial Involving OrbusNeich Distal Protection System (TODOS) trial. JACC Cardiovasc. Interv. 5, 1223–1230 (2012).

163. Stonel, L. et al. Coronary abciximab and aspiration therapy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 307, 1811–1826 (2012).

164. Friebert, O. et al. Thrombectomy during ST-segment elevation myocardial infarction. N. Engl. J. Med. 369, 1587–1597 (2013).

165. Jolly, S. S. et al. Randomized trial of primary PCI with or without routine manual thrombectomy. N. Engl. J. Med. 367, 1389–1398 (2012).

166. De Porcelli, A. et al. Thrombectomy in patients with ST-segment elevation myocardial infarction presenting late after symptom onset. JACC Cardiovasc. Interv. 9, 1135–1142 (2016).

167. Hibi, K. et al. A randomized study of distal filter protection versus conventional treatment during percutaneous coronary intervention in patients with attenuated plaque identified by intravascular ultrasound. JACC Cardiovasc. Interv. 11, 1545–1555 (2018).

168. Feistritzer, H. J. et al. Long-term outcome after thrombus aspiration in acute myocardial infarction: results from the TATORTNSTEMI trial: thrombus aspiration in acute myocardial infarction. Clin. Res. Cardiol. 99, 167–174 (2010).

169. Kleinbongard, P. et al. Lessons from human coronary aspirate. J. Mol. Cell. Cardiol. 52, 890–896 (2012).

170. Horderman, D. et al. Coronary-tor-retroflow is caused by shedding of active tissue from dissected atherosclerotic plaque. Blood 99, 2794–2800 (2002).

171. Rogers, C. et al. Embolic protection with filtering or occlusion balloons during primary angioplasty: vein graft stenting retrieves identical volumes and sizes of particulate debris. Circulation 109, 1735–1740 (2004).

172. Patti, G. et al. Clinical benefit of stent pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 15 randomized trials. Circulation 123, 1622–1632 (2011).

173. Bell, R. M. & Yellon, D. M. Atorvastatin, administered at the onset of reperfused lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. 41, 515–525 (2003).

174. Efthymiou, C. A., Mocanu, M. M. & Yellon, D. M. Atorvastatin and myocardial reperfusion injury. New pleiotropic effect implicating multiple preservation signaling. J. Cardiovasc. Pharmacol. 45, 247–252 (2005).

175. Mendetta, G. et al. Intraaortic balloon counterpulsation during ischemia exerts cardioprotective effects. J. Am. Coll. Cardiol. 74, 475–477 (2019).

176. Valgimigli, M. et al. ESC focused update on dual antiplatelet therapy: latest update and recent developments in collaboration with EACTS, The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 39, 213–260 (2018).

177. Kamran, H. et al. Oral antiplatelet therapy after acute coronary syndrome: a review. JAMA 325, 1545–1555 (2021).

178. Patti, G. et al. Randomized trial of high loading dose of clopidogrel for reducing periprocedural myocardial infarction in patients undergoing coronary revascularization. Results from the ARMYDA-2 (antiplatelet therapy for reducing peri-operative myocardial infarction during angioplasty) study. Circulation 111, 2099–2106 (2005).

179. Yang, X. M. et al. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J. Cardiovasc. Pharmacol. Ther. 18, 251–262 (2013).

180. Cohen, M. V. & Downey, J. M. What are optimal P2Y12 inhibitor and schedule of administration in patients with acute coronary syndromes? J. Cardiovasc. Pharmacol. Ther. 25, 121–130 (2020).

181. He, Z., Davidson, S. M. & Wiviott, D. S. The importance of clinically relevant background therapy in cardioprotective studies. Basic Res. Cardiol. 115, 69 (2020).

182. Schupeck, S. et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N. Engl. J. Med. 381, 1522–1534 (2019).

183. Karathanos, A. et al. Routine glycoprotein IIb/IIIa inhibitor therapy in ST-segment elevation myocardial infarction: a meta-analysis. Can. J. Cardiol. 35, 1576–1588 (2019).

184. McCartney, P. J. et al. Effect of low-dose intracoronary alteplase during primary percutaneous coronary intervention on microvascular obstruction in patients with acute myocardial infarction: a randomized clinical trial. JAMA 321, 56–68 (2019).

185. Niccoli, G. et al. Open-label, randomized, placebo-controlled evaluation of intracoronary adenosine or nitroglycerin after thrombus aspiration during primary percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc. Interv. 17, 959–969 (2020).

186. Nazir, S. A. et al. Strategies to attenuate microvascular obstruction during PCI: the randomized reperfusion facilitated by local adjunctive therapy in STElevation myocardial infarction (LATE) trial. Eur. Heart J. 37, 1910–1919 (2016).

187. Bullock, H., Sikker, A., Loke, Y. K., Garcia-Dorado, D. & Chang, H. H. Randomized clinical trial of a fibrinolytic agent as an adjunct to reperfusion in STElevation myocardial infarction patients: an updated meta-analysis of randomized controlled trials. Int. J. Cardiol. 202, 228–237 (2016).

188. Kaplan, B. M. et al. Treatment of no-reflow in degenerated human carotid plaques: comparison of intracoronary verapamil and nitroglycerin. Catheter. Cardiovasc. Diagn. 39, 118–118 (1996).
209. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

210. Liberaire, L. et al. Interleukin-1beta mediates arterial thrombus formation via NETosis in tissue factor. J. Clin. Med. 8, 2072 (2019).

211. Ridker, P. M. et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur. Heart J. 39, 3469–3507 (2018).

212. Cao, D., Chiarito, M. & Mehran, R. Treating inflammation prior to percutaneous coronary intervention: does the heart care? Circ. Cardiovasc. Interv. 13, e009127 (2020).

213. Morton, A. C. et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA heart study. Eur. Heart J. 36, 577–584 (2015).

214. Kleveland, O. et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur. Heart J. 37, 2406–2413 (2016).

215. Meyer, M. A. S. et al. Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (The IMICAT trial): a double-blind, placebo-controlled, single-center randomized clinical trial. Circulation 143, 1841–1851 (2021).

216. Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845–1855 (2021).

217. Tardif, J. C. et al. Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J. Am. Coll. Cardiol. 61, 2048–2055 (2013).

218. Deftereos, S. et al. Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study. Circulation 132, 1395–1405 (2015).

219. Martinez, G. J. et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc. 4, e002128 (2015).

220. Akodad, M. et al. COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch. Cardiovasc. Dis. 110, 395–402 (2017).

221. Hennessy, T. et al. The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. Am. Heart J. 215, 62–69 (2019).

222. Shah, B. et al. Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial. Circ. Cardiovasc. Interv. 13, e008177 (2020).

223. Cole, J. et al. Colchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention: the COPE-PCI pilot trial. Circ. Cardiovasc. Interv. 14, e009992 (2021).

224. Varga, Z. et al. Endothelial cell infection and endothelitis in COVID-19. Lancet 395, 1417–1418 (2020).

225. Gu, S. X. et al. Thrombocytopenia and endothesiopathy: crucial contributors to COVID-19 thromboinflammation. Nat. Rev. Cardiol. 18, 194–209 (2021).

226. Czanano, P. et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic Transl. Sci. 6, 202–218 (2021).

227. Wagner, J. U. G. et al. Increased susceptibility of human endothelial cells to infections by SARS-CoV-2 variants. Basic Res. Cardiol. 116, 42 (2021).

228. Basso, C. et al. Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study. Eur. Heart J. 41, 3827–3835 (2020).

229. Halasinski, M. K. & Vander Heide, R. S. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. Cardiovasc. Pathol. 50, 107300 (2021).

230. Pellegrini, D. et al. Microthrombi as a major cause of cardiac injury in COVID-19: a pathologic study. Circulation 145, 1021–1042 (2021).

231. Blasco, A. et al. Assessment of neutrophil extracellular traps in coronary thrombus of a case series of patients with COVID-19 and myocardial infarction. JAMA Cardiol. 6, 469–474 (2021).

232. Stark, K. & Massberg, S. Interplay between inflammation and thrombosis in cardiovascular pathology. Nat. Rev. Cardiol. 18, 666–682 (2021).

233. Heusch, G. & Erbel, R. Coronare mikroembolisation. Desch. Arztebl. 99, A2200–A2202 (2002).

234. Hildebrandt, H. A. et al. Quantification and characterization of released plaque material during biodegradable vascular scaffold implantation into right coronary artery lesions by multimodality intracoronary imaging. Eurointervention 12, 1481–1489 (2016).

235. Erbel, R. & Heusch, G. Coronary microembolization - its role in acute coronary syndromes and interventions. Herz 24, 558–575 (1999).

Acknowledgements

PK. and G.H. receive support from the German Research Foundation (SFB 1116 B8) and the European Union COST ACTION (CA 16225). The authors are grateful to their former colleagues Raimund Erbel (University of Essen Medical School, Germany) and Michael Haude (Rheinlandklinikum Neuss, Germany) for excellent collaborations in this field.

Author contributions

PK. and G.H. researched data for the article and discussed its content. G.H. wrote the manuscript, and both authors reviewed and edited it before submission.

Competing interests

The authors declare no competing interests.

Peer review information

Nature Reviews Cardiology thanks Niels van Royen and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. © Springer Nature Limited 2021